News

The first-in-class mutant collagenase RJV001 successfully pa...

2022-06-17

On June 13, 2022, the US FDA approved the phase I clinical trial of the RJV001 (NCT04821648). A total of 18 patients were enrolled and reached the end of the study, and all three doses were safe and w...

Rejuven Invited to Attend the Enterprise Exhibition Day of J...

2022-06-17

on February 28, 2022, Rejuven participated in the Enterprise Exhibition Day of Johnson & Johnson Innovation held in Pudong New Area, Shanghai, sharing the R&D progress and products in the biomedical f...

Rejuven Awarded “High Technology Expertise”

2022-06-15

Rejuven continues to research biological drugs supported by Torch Program and has developed its core independent intellectual property rights in recent years. On December 16, 2021, Rejuven Dermaceutial was awarded “High Technology Expertise” in the first nominated high-tech enterprises list.

Rejuven Invited to Attend the Fourth China International Imp...

2021-12-20

On November 5, 2021, the fourth China International Import Expo (CIIE) was held in Shanghai. A total of 58 countries and 3 international organizations participated in the national exhibition, and near...

Rejuven won the first prize of “Startup @ Investment” -- H...

2021-12-20

On May 8, 2021, the final competition of "Startup @ Investment" Healthcare Innovation and Entrepreneurship was held in the Science and Technology Park of Hangzhou Normal University in Yuhang District....

Rejuven Dermaceutical is awarded Skincare of the Future Quic...

2021-12-20

Johnson & Johnson Innovation and Johnson & Johnson Consumer Inc. have named Rejuven Dermaceutical an awardee in the Skincare of the Future QuickFire Challenge, in collaboration with Alibaba’s TMALL.

Copyright © 2019 Hangzhou Rejuven Dermaceutical Co., Ltd. All Rights Reserved Zhejiang Public Network Security No. 330108020005711备案号:浙ICP备15013641号